Marco Herling
Leipzig, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 164 publications
Prognostic relevance of RUNX1 mutations at acute myeloid leukemia diagnosis and as measurable residual disease marker before and after allogeneic stem cell transplantation.
Journal: Haematologica
Published: May 14, 2026
Low muscle quality, but not muscle mass, in abdominal CT-scans associates with adverse outcomes in AML patients undergoing an allogeneic stem cell transplantation.
Journal: Bone marrow transplantation
Published: April 11, 2026
Relapse risk after FLAMSA RIC based allogeneic hematopoietic stem cell transplantation in heavily pretreated AML patients.
Journal: Bone marrow transplantation
Published: March 20, 2026
Goals-of-care transition after an allogeneic hematopoietic stem-cell transplantation: A cross-sectional survey among hematologists on associated challenges.
Journal: Bone marrow transplantation
Published: March 12, 2026
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells.
Journal: Bone marrow transplantation
Published: February 19, 2026
We included a total of 87 patients who received CAR T-cell therapy: 54 with none/mild chronic kidney disease (CKD) and 33 with moderate/severe CKD.
Journal: Transplantation and cellular therapy
Published: February 10, 2026
How to talk about death? A cross-sectional survey on patients', informal caregivers' and health care professionals' views in the setting of allogenic hematopoietic stem cell transplantation.
Journal: Annals of hematology
Published: January 15, 2026
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party.
Journal: Journal of hematology & oncology
Published: December 27, 2025
Characteristics, patterns of care and outcomes of patients with T-cell lymphoma-associated hemophagocytic lymphohistiocytosis: a single-center retrospective analysis.
Journal: Leukemia & lymphoma
Published: December 05, 2025
Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.
Journal: HemaSphere
Published: October 27, 2025
Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Journal: Leukemia & lymphoma
Published: October 24, 2025
Last Updated: 09/26/2026